Given the importance of minimizing financial toxicity, for patients who have borderline unfavorable intermediate characteristics, is it reasonable to ...
                    
	
	
		        	
	
	
New answer by  (November 4, 2024)
Summary: The short answer is that APP4 is unlikely to improve risk prognostication to the extent to which other advanced biomarkers (GC, MMAI, etc.) do. It is also unlikely ei...